Gentris Corporation Names New Chief Scientific Advisor
MORRISVILLE, N.C., Nov. 4, 2010 /PRNewswire/ -- Gentris Corporation (www.gentris.com), a global leader in applied clinical pharmacogenomics, announced today that Howard McLeod, Pharm.D., from The University of North Carolina at Chapel Hill (UNC) has become the Company's first Chief Scientific Advisor. Dr. McLeod, an internationally recognized expert in pharmacogenomics and personalized medicine, is the Fred N. Eshelman Distinguished Professor and Director of the Institute for Pharmacogenomics and Individualized Therapy. He holds academic appointments in the UNC Schools of Pharmacy and Medicine as well as the Lineberger Comprehensive Cancer Center.
Dr. McLeod is actively involved in global pharmacogenomics initiatives. He serves as Principal Investigator for the CREATE Pharmacogenomics Research Network and is a member of the FDA Committee on Clinical Pharmacology. He is also Vice Chairman for Pharmacogenomics with the NIH Cancer and Leukemia Group B Pharmacology and Experimental Therapeutics Committee. As Director of the PharmacoGenetics for Every Nation Initiative (PGENI), he works with scientists, medical experts, and government officials around the world to assist developing countries as they take advantage of pharmacogenomic innovations to improve decision-making in the use of biotechnology and pharmaceutical products.
Dr. McLeod has published more than three hundred and eighty peer-reviewed papers on pharmacogenomics, applied therapeutics, or clinical pharmacology and serves on the editorial boards of seven scientific journals. Additionally, he sits on numerous advisory boards for industry and non-profit organizations.
Gentris Corporation, founded in 2001, is located in the heart of Research Triangle Park where it provides biotechnology and pharmaceutical companies with cutting-edge scientific guidance in patient clinical-trial selection and strategies to reduce adverse drug reactions. The Company